Area of research
Pulmonary and Respiratory Medicine · Gastroenterology
Research interest
Despite the higher chance of cure rates, cancer is the number 1 cause of death. Systemic treatment of cancer, the area of expertise of the medical oncologist, is increasingly responsible for the higher cure rates and the higher chances of turning cancer into a chronic disease. Research in the department of Medical Oncology consists of 2 researchlines: (1) immunology/therapy including our research laboratory led by Prof van der Burg and (2) personalised pharmacotherapy in oncology led by Prof Gelderblom.
MANEUVER: A Phase III study of pimicotinib to assess efficacy and safety in tenosynovial giant cell tumor patients.
Procedures of data merging in precision cancer medicine: the PRIME-ROSE project.
The trajectory of fatigue over time in breast cancer patients treated with chemotherapy: exploring the effect of anthracycline-based chemotherapy.
'Crossing borders' in data standardisation: application of OMOP CDM in an international clinical trial network in precision cancer medicine.
Microbial Metabolic Pathways Guide Response to Immune Checkpoint Blockade Therapy.
Prospective evaluation of genomics-guided off-label treatment.
Figure S1 from Microbial Metabolic Pathways Guide Response to Immune Checkpoint Blockade Therapy
Table S6 from Microbial Metabolic Pathways Guide Response to Immune Checkpoint Blockade Therapy
BRAFV600E-mutated central nervous system tumors benefit from treatment with dabrafenib plus trametinib: Results from the Drug Rediscovery Protocol
Figure S7 from Microbial Metabolic Pathways Guide Response to Immune Checkpoint Blockade Therapy
Table S3 from Microbial Metabolic Pathways Guide Response to Immune Checkpoint Blockade Therapy
Figure S2 from Microbial Metabolic Pathways Guide Response to Immune Checkpoint Blockade Therapy
Figure S9 from Microbial Metabolic Pathways Guide Response to Immune Checkpoint Blockade Therapy
Table S8 from Microbial Metabolic Pathways Guide Response to Immune Checkpoint Blockade Therapy
Figure S6 from Microbial Metabolic Pathways Guide Response to Immune Checkpoint Blockade Therapy
Table S7 from Microbial Metabolic Pathways Guide Response to Immune Checkpoint Blockade Therapy
Table S4 from Microbial Metabolic Pathways Guide Response to Immune Checkpoint Blockade Therapy
Table S1 from Microbial Metabolic Pathways Guide Response to Immune Checkpoint Blockade Therapy
Figure S4 from Microbial Metabolic Pathways Guide Response to Immune Checkpoint Blockade Therapy
Figure S3 from Microbial Metabolic Pathways Guide Response to Immune Checkpoint Blockade Therapy
Survival of patients with colorectal or pancreatic cancer who received UGT1A1 genotype-guided dosing of irinotecan in the Netherlands (2017–2024): a retrospective, multicentre cohort study
Figure S5 from Microbial Metabolic Pathways Guide Response to Immune Checkpoint Blockade Therapy
Table S5 from Microbial Metabolic Pathways Guide Response to Immune Checkpoint Blockade Therapy
Figure S8 from Microbial Metabolic Pathways Guide Response to Immune Checkpoint Blockade Therapy
Data from Microbial Metabolic Pathways Guide Response to Immune Checkpoint Blockade Therapy
Table S2 from Microbial Metabolic Pathways Guide Response to Immune Checkpoint Blockade Therapy
Dose-individualisation of fluoropyrimidines based on pre-treatment serum uracil levels: the Alpe2U study
A phase 4, multicenter, global clinical study to evaluate discontinuation and rechallenge of pexidartinib in patients with tenosynovial giant cell tumor previously treated with pexidartinib.
TEIPP-vaccination in checkpoint-resistant non-small cell lung cancer: a first-in-human phase I/II dose-escalation study.
Guidelines for Next-Generation Sequencing in Sarcoma Diagnosis and Treatment